207 related articles for article (PubMed ID: 24700612)
1. Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment.
Warren CR; Grindel BJ; Francis L; Carson DD; Farach-Carson MC
J Cell Biochem; 2014 Jul; 115(7):1322-33. PubMed ID: 24700612
[TBL] [Abstract][Full Text] [Related]
2. Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells.
Grindel BJ; Martinez JR; Tellman TV; Harrington DA; Zafar H; Nakhleh L; Chung LW; Farach-Carson MC
Sci Rep; 2018 May; 8(1):7262. PubMed ID: 29740048
[TBL] [Abstract][Full Text] [Related]
3. SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
Brasil da Costa FH; Lewis MS; Truong A; Carson DD; Farach-Carson MC
PLoS One; 2020; 15(5):e0230354. PubMed ID: 32413029
[TBL] [Abstract][Full Text] [Related]
4. Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior.
Grindel BJ; Martinez JR; Pennington CL; Muldoon M; Stave J; Chung LW; Farach-Carson MC
Matrix Biol; 2014 Jun; 36():64-76. PubMed ID: 24833109
[TBL] [Abstract][Full Text] [Related]
5. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.
Datta MW; Hernandez AM; Schlicht MJ; Kahler AJ; DeGueme AM; Dhir R; Shah RB; Farach-Carson C; Barrett A; Datta S
Mol Cancer; 2006 Mar; 5():9. PubMed ID: 16507112
[TBL] [Abstract][Full Text] [Related]
6. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.
Farach-Carson MC; Warren CR; Harrington DA; Carson DD
Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398
[TBL] [Abstract][Full Text] [Related]
7. Flipping the Molecular Switch: Influence of Perlecan and Its Modifiers in the Tumor Microenvironment.
Cruz LA; Tellman TV; Farach-Carson MC
Adv Exp Med Biol; 2020; 1245():133-146. PubMed ID: 32266656
[TBL] [Abstract][Full Text] [Related]
8. Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression.
Sadatsuki R; Kaneko H; Kinoshita M; Futami I; Nonaka R; Culley KL; Otero M; Hada S; Goldring MB; Yamada Y; Kaneko K; Arikawa-Hirasawa E; Ishijima M
J Orthop Res; 2017 Apr; 35(4):837-846. PubMed ID: 27238423
[TBL] [Abstract][Full Text] [Related]
9. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.
Ishijima M; Suzuki N; Hozumi K; Matsunobu T; Kosaki K; Kaneko H; Hassell JR; Arikawa-Hirasawa E; Yamada Y
Matrix Biol; 2012 May; 31(4):234-45. PubMed ID: 22421594
[TBL] [Abstract][Full Text] [Related]
10. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.
Grindel B; Li Q; Arnold R; Petros J; Zayzafoon M; Muldoon M; Stave J; Chung LW; Farach-Carson MC
Oncotarget; 2016 Mar; 7(9):10433-47. PubMed ID: 26862737
[TBL] [Abstract][Full Text] [Related]
11. The heparan sulphate deficient Hspg2 exon 3 null mouse displays reduced deposition of TGF-β1 in skin compared to C57BL/6 wild type mice.
Shu C; Smith SM; Melrose J
J Mol Histol; 2016 Jun; 47(3):365-74. PubMed ID: 27098652
[TBL] [Abstract][Full Text] [Related]
12. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis.
Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J
Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652
[TBL] [Abstract][Full Text] [Related]
13. Perlecan/Hspg2 deficiency alters the pericellular space of the lacunocanalicular system surrounding osteocytic processes in cortical bone.
Thompson WR; Modla S; Grindel BJ; Czymmek KJ; Kirn-Safran CB; Wang L; Duncan RL; Farach-Carson MC
J Bone Miner Res; 2011 Mar; 26(3):618-29. PubMed ID: 20814969
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element.
Iozzo RV; Pillarisetti J; Sharma B; Murdoch AD; Danielson KG; Uitto J; Mauviel A
J Biol Chem; 1997 Feb; 272(8):5219-28. PubMed ID: 9030592
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.
Kazanskaya GM; Tsidulko AY; Volkov AM; Kiselev RS; Suhovskih AV; Kobozev VV; Gaytan AS; Aidagulova SV; Krivoshapkin AL; Grigorieva EV
Histochem Cell Biol; 2018 Mar; 149(3):235-244. PubMed ID: 29322326
[TBL] [Abstract][Full Text] [Related]
16. Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes.
Johnson BB; Cosson MV; Tsansizi LI; Holmes TL; Gilmore T; Hampton K; Song OR; Vo NTN; Nasir A; Chabronova A; Denning C; Peffers MJ; Merry CLR; Whitelock J; Troeberg L; Rushworth SA; Bernardo AS; Smith JGW
Cell Rep; 2024 Jan; 43(1):113668. PubMed ID: 38198277
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional complexity of the HSPG2 gene in the human mast cell line, HMC-1.
Lord MS; Jung M; Cheng B; Whitelock JM
Matrix Biol; 2014 Apr; 35():123-31. PubMed ID: 24365408
[TBL] [Abstract][Full Text] [Related]
18. Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels.
Hubka KM; Carson DD; Harrington DA; Farach-Carson MC
Acta Biomater; 2019 Oct; 97():385-398. PubMed ID: 31351252
[TBL] [Abstract][Full Text] [Related]
19. Elevated hypertrophy, growth plate maturation, glycosaminoglycan deposition, and exostosis formation in the
Shu CC; Smith SM; Little CB; Melrose J
Biochem J; 2019 Jan; 476(2):225-243. PubMed ID: 30563944
[TBL] [Abstract][Full Text] [Related]
20. Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle.
Yamashita Y; Nakada S; Yoshihara T; Nara T; Furuya N; Miida T; Hattori N; Arikawa-Hirasawa E
Sci Rep; 2018 May; 8(1):7766. PubMed ID: 29773865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
